Year-end Sale % OFF 
Abstract
NBS for SCID has been universally implemented in the U.S. Patients with DNA double-strand break repair defects RS-SCID constitute a rare sub-group, who are susceptible to developing malignancies and non-lymphoid comorbidities. Here, we describe three patients and discuss challenges in clinical management of RS-SCID defects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
